Clinical Trial: The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.

U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07592754) titled 'The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.' on May 12.

Brief Summary: KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This is a multi-center, single-arm, open-label, early exploratory clinical study. The objective of this study is to evaluate the safety and preliminary efficacy of KSVCBD injection in AQP4-positive Neuromyelitis Optica Spectrum Disorder

Study Start Date: May 15

Study Type: INTERVENTIONAL

Condition: Neuromyelitis Optica Spectrum Disease (NMOSD)

Intervention: BIOLOGICAL: KSVCBD injection

KSVCBD injection is a CD19/BCMA-targe...